BioNTech SE (B1NT34)

Overview

BioNTech SE is a forward-thinking biotechnology company, primarily focused on the development and commercialization of novel immunotherapies for cancer and various infectious diseases. With its foundation dating back to 2008, the company has quickly positioned itself as a leader in the biotech industry, led from its headquarters in Mainz, Germany. BioNTech's innovative approach leverages a wide array of product candidates within the FixVac series and other proprietary technologies across different stages of clinical trials, aiming to revolutionize treatment options for patients worldwide. The company's dynamic research and development efforts are supported by robust collaborations and strategic partnerships with several key players in the pharmaceutical and biotechnology sectors, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Ryvu Therapeutics S.A, and the Coalition for Epidemic Preparedness Innovations (CEPI), underscoring its commitment to advancing healthcare solutions on a global scale.

Products and Services

• FixVac Product Candidates:

  BioNTech is in the process of developing several FixVac product candidates targeting various cancers. These include BNT111 for advanced melanoma, BNT112 for prostate cancer, BNT113 for HPV 16+ head and neck cancers, BNT114 for triple negative breast cancer, BNT115 in ovarian cancer, and BNT116 for non-small cell lung cancer, each at various stages of clinical trials.

• Additional Oncology Candidates:

  The company's active oncology pipeline extends with BNT122 for melanoma and solid tumors, BNT131, BNT141, BNT142 for multiple solid tumors, and BNT151, BNT152, BNT153 for further solid tumor indications. BNT211, BNT221, BNT311, and BNT312 are also under development for various solid tumors and specific cancers such as pancreatic and non-small cell lung cancer.

• Immunomodulators and Monoclonal Antibodies:

  Beyond proprietary vaccine platforms, BioNTech is working on BNT321, an IgG1 monoclonal antibody for pancreatic cancer, and BNT411, a small molecule immunomodulator for solid tumors, highlighting its diversified approach to cancer treatment.

• Prophylactic Vaccines:

  BioNTech's expertise is not limited to cancer therapeutics. The company is also pioneering the development of prophylactic vaccines against infectious diseases such as shingles, malaria, tuberculosis, HSV-2, leveraging its technological platforms to meet global health challenges.